CEO Marc Coucke co-founded Omega Pharma NV company in 1987. Omega Pharma's first product was generic shampoo, which it sold to pharmacies. Omega Pharma NV is a Belgium-based provider of healthcare products and services for the pharmacies and other medical sectors. The Company specializes in the development, marketing and sales of health and personal care products, which can be obtained by the end-consumer without medical prescription (over the counter or OTC products). Omega Pharma NV consists of five business units, and is engaged in the provision of consumer-oriented medicines and healthcare products. It is composed of Omega Pharma Belgium, Omega Pharma France, Omega Pharma Northern Europe, Omega Pharma Southern Europe and Omega Pharma Rest of the World. As of December 31, 2008, the Company operated in over 30 countries, including most of the European countries, as well as Australia, New Zealand and Argentina.

Sanofi Pasteur helps you guard against getting sick in the first place. The company is the US vaccines division of French drugmaker Sanofi-Aventis. It makes vaccines that protect against such infectious diseases as influenza, polio, and meningitis. Some of its top sellers are flu vaccines, childhood combination vaccines, and adult booster shots. It also makes travelers' vaccines that keep globetrotters safe from typhoid, cholera, yellow fever, and the like. Projects in development include improved vaccines for influenza, preventative vaccines for HIV and dengue fever, and therapeutic vaccines for cancer.

Since its founding in 1928, the Hannah Research Institute has conducted research aimed at making food healthier and safer. The institute, which has links to the University of Glasgow and the Scottish Agricultural College, receives funding from the Scottish Government, medical charities, and pharmaceutical companies. Its Biomedical division conducts research on the links between health and nutrition, while the CHARIS Food Research division ... researches food. In particular, the Institute seeks to understand how environment, physiology, genetics, and other factors affect susceptibility to breast cancer, cardiovascular disease, diabetes, and obesity.

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Compugen Ltd. company was founded in 1993 and is based in Tel Aviv, Israel. Compugen Ltd. (Compugen) is engaged in drug and diagnostic product candidate discovery and the commercialization of such candidates through early-stage licensing and co-development agreements. The Company’s business is focused on developing and using predictive computer-based discovery platforms to discover therapeutic drug candidates and diagnostic biomarker candidates. The Company uses experimental biological processes to validate product candidates discovered by its predictive platforms. Its initial discovery platforms focused mainly on cancer, cardiovascular and immune-related diseases. In July 2008, Compugen announced results from an in vivo study of CGEN-25007, a peptide antagonist of the gp96 protein. The data indicate that CGEN-25007 has immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases and other immune related pathologies.

Kyowa Hakko Kirin Co., Ltd., formerly KYOWA HAKKO KOGYO CO., LTD., is a Japan-based manufacturer that has five business segments. The Medical Product segment is engaged in the manufacture, sale and promotion of medical products for hospital use, as well as the provision of technologies for antibody drug creation, the development of candidate substances for new drugs and the supply of clinical test reagents. The Biochemical segment offers medical and industrial materials, mainly amino and nucleic acids, as well as healthcare items and products for agriculture and fishery uses. It also designs and constructs facilities. The Chemical Product segment provides solvents, plasticizers, materials for plasticizers and functional products, among others. Its Food segment supplies seasonings, materials for confectionery and bread making, processed food products and others. The Others segment is involved in the wholesale and distribution businesses, as well as the provision of industrial alcohol.

GlaxoSmithKline Biologicals s.a. company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc. Glaxosmithkline Biologicals S.A. engages in the research, development, manufacture, and supply of vaccines. Its vaccination products are used to tackle various diseases, such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B. Glaxosmithkline Biologicals S.A. was formerly known as SmithKline Beecham Biologicals S.A. and changed its name to GlaxoSmithKline Biologicals S.A. in 2000.

Vermillion, Inc. is involved in the discovery, development and commercialization of diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers (known as translational proteomics) for developing a procedure to measure a property or concentration of an analyte (known as an assay) and commercializing diagnostic tests. Vermillion has focuses in the areas of oncology, hematology, cardiology and women’s health. Vermillion’s focus on translational proteomics enables it to address the market for diagnostic tests that measure multiple protein biomarkers. In January 2010, the Company emerged from protection under Chapter 11 of the United States Bankruptcy Code.

Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland. Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company's clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of Albuferon; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.